Jeffrey S. Hackman - 12 Oct 2026 Form 4 Insider Report for FENNEC PHARMACEUTICALS INC. (FENC)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: FENC
Reported as of: 12 Oct 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Oct 2026, 16:05:17 UTC
Prior SEC filing: 01 Oct 2026
Source filing: View source filing
Reporting owner signature: /s/ Jeffrey Hackman

Key filing fact

Jeffrey S. Hackman filed Form 4 for FENNEC PHARMACEUTICALS INC. (FENC) on 13 Oct 2026.

Key facts

This page summarizes Jeffrey S. Hackman's Form 4 filing for FENNEC PHARMACEUTICALS INC. (FENC).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 13 Oct 2026, 16:05.

Change

Previous filing in this sequence was filed on 01 Oct 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001926254 Primary reporting owner

Hackman Jeffrey S.

Relationship: Chief Executive Officer, Director
Address: 68 TW ALEXANDER DRIVE, PO BOX 13628, RESEARCH TRIANGLE PARK
Signature: /s/ Jeffrey Hackman
Signature date: 13 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

FENC transaction

Common Shares

Award

Transaction value
Shares: +2,224
Change %: +3.3%
Price: $5.53^*
Shares after: 69,685
Date: 12 Oct 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The Issuer's common shares were acquired pursuant to the Fennec Pharmaceuticals Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of April 9, 2026 through October 12, 2026.

Footnote F2

In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on the Nasdaq Capital Market on April 9, 2026.